Abstract
A deeper understanding of the mechanisms of their cardiotoxicity reveals that there is no 'safe' dose of anthracyclines. However, certain risk factors, such as higher lifetime anthracycline cumulative doses, higher anthracycline dose rates, female sex, longer follow-up, younger age at anthracycline treatment and cardiac irradiation, are associated with more severe cardiotoxicity. We advocate the use of dexrazoxane to limit the cardiotoxic effects of anthracycline chemotherapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 628-638 |
| Number of pages | 11 |
| Journal | Current Opinion in Pediatrics |
| Volume | 30 |
| Issue number | 5 |
| DOIs | |
| State | Published - Jan 1 2018 |
| Externally published | Yes |
Keywords
- Anthracycline
- Cardio-oncology
- Cardiotoxicity
- Childhood cancer
- Survivorship
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
Fingerprint Dive into the research topics of 'Cardiovascular disease in survivors of childhood cancer'. Together they form a unique fingerprint.
Cite this
Bansal, N., Amdani, S. M., Hutchins, K. K., & Lipshultz, S. E. (2018). Cardiovascular disease in survivors of childhood cancer. Current Opinion in Pediatrics, 30(5), 628-638. https://doi.org/10.1097/MOP.0000000000000675